Please assess the completion status of the following clinical trial:

Trial Title: TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent,~* Age of 18 to 70 years,~* Life expectancy of at least 6 month,~* Ability of subject to understand character and individual consequences of clinical trial,~* Histologically confirmed locally advanced (stage III or IV), non-metastatic squamous cell carcinoma of oro-, hypopharynx and larynx (T2-4, any N, M0),~* Oral cavity or oro- , hypopharynx or laynx as the primary tumor site,~* At least one uni-measurable lesion according to the RECIST criteria, Karnofsky Performances Status \> 70%,~* Adequate bone marrow function: neutrophils \> 1.5 x 109/L, platelets \> 100 x 109/L, hemoglobin \> 10.0 g/dL,~* Adequate liver function: Bilirubin \< 1.5 mg/dL, SGOT, SGPT \< 3 x ULN, GGT \< 5 x ULN,~* Adequate renal function: GFR\> 70 ml/min,~* Negative serum/urine Beta-HCG test in women of childbearing potential,~* Women of childbearing potential: willingness to use effective contraceptive method, defined as the concomitant use of either an intrauterine pessary (IUP) or contraceptive pill and in both cases, condoms for the treatment duration and 2 months thereafter. Women of non-childbearing potiential are those who are post-menopausal for at least 1 year or sterilized,~* Men of procreative potential: willingness for effective prevention of procreation, defined as a use of condoms and a use of either an intrauterine pessary (IUP) or a contraceptive pill by his partner for the treatment duration and 2 months thereafter,~* Subject's consent to collect blood and/or tumor tissue samples for proteomics and genomics. If a patient does not consent, no samples for proteomics and genomics will be taken. Nonetheles, he/she may be enroled in the study~Exclusion Criteria:~* Previous systemic chemotherapy, radiotherapy or surgery for carcinoma of the head, neck and larynx,~* Nasopharyngeal Carcinoma,~* Prior exposure to EGFR pathway targeting therapy,~* Evidence of distant metastases.~* Other serious illness or medical conditions:~* Unstable cardiac disease despite treatment, congestive heart failure NYHA grade 3 and 4,~* Significant neurologic or psychiatric disorders including dementia or seizures,~* Active disseminated intravascular coagulation,~* Other serious underlying medical conditions which in the opinion of investigator could impair the ability of the patient to participate in the study,~* Symptomatic peripheral neuropathy Common Toxicity Criteria (CTC) grade 2 or higher,~* ototoxicity CTC grade 2 or higher, except if due to trauma or mechanical impairment due to tumor mass,~* Participation in other interventional trial within the last 30 days§§,~* Surgery within the last 30 days,~* Known allergic/hypersensitivity reaction to any drugs scheduled for the study treatment,~* Women: pregnant or breast-feeding,~* Known drug abuse,~* Other previous malignancy within 5 years, with exception of a history of a previous, adequately treated, basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix,~* Legal incapacity or limited legal capacity,~* Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- treatment arm (Type: EXPERIMENTAL): patients receive induction chemotherapy with TPF for a maximum of 3 cycles followed by radioimmunotherapy with cetuximab as intensity-modulated radiotherapy (IMRT) plus carbon ion boost

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues